Receptor names describe which signalling target a molecule acts on, not how strong or how safe it is. In metabolic peptide literature you will mainly meet three: the GLP-1 receptor, the GIP receptor and the glucagon receptor. GLP-3 is used informally here as a customer-facing name for retatrutide because it acts at those three named targets; it is not itself a receptor name. GLP-2 is a separate target.
What each name refers to
| GLP-1 receptor | The target of glucagon-like peptide-1 receptor agonists. Semaglutide is described in its official labelling as a GLP-1 receptor agonist. |
|---|---|
| GIP receptor | The target of glucose-dependent insulinotropic polypeptide, a second incretin signal studied alongside GLP-1. |
| Glucagon receptor | A distinct target usually discussed in the context of glucose output and energy expenditure research. |
| “GLP-3” | Not a recognised receptor name. If a listing uses it, treat the description as unreliable. |
Why the count of targets matters in reading
Retatrutide is described in the published phase 2 trial report as an agonist at the GLP-1, GIP and glucagon receptors , three targets, reported in a 2023 randomized, placebo-controlled study of 338 adults over 48 weeks. Receptor activity and clinical outcomes remain separate questions. [Jastreboff et al., 2023]
Counting targets tells you what a study was designed to interrogate. It does not tell you that more targets produce a better outcome, nor that findings from one molecule transfer to another molecule acting on an overlapping receptor. Every additional target is an additional set of expected and unexpected effects that a trial has to measure.
How the mechanism sentence is usually built
Official semaglutide labelling keeps two effects apart. One is appetite: it states that GLP-1 regulates appetite and calorie intake, that GLP-1 receptors are present in brain regions involved in appetite regulation, and that calorie intake is decreased likely through an effect on appetite. The other is blood glucose: glucose-dependent insulin secretion and reduced glucagon secretion lower blood glucose. Delayed gastric emptying is described separately again. Reduced eating is therefore not presented as a consequence of the insulin and glucagon actions. These are statements from labelling for specific approved formulations , not general claims about any vial sharing an ingredient name. [US semaglutide prescribing information]
A short reading checklist
- Name the receptor or receptors the source actually says the molecule acts on.
- Check whether the source is a trial report, a regulated label or promotional text.
- Separate mechanism statements from outcome statements in your notes.
- Reject invented receptor names and unnamed “next-generation” claims.
- Never carry a trial result across to a differently manufactured product.
Where the naming confusion comes from
Marketing copy often compresses “acts at three receptors” into a single invented label that sounds like a generation number. Reading the receptor list literally, in the words of the primary source, is the fastest way to notice when a description has drifted away from the underlying science.